The pandemic affected every aspect of our lives, from our portfolios to the way we interact with our friends and loved ones. Despite these challenges, one industry stood out above the rest in 2020: biotech.
In the face of an unprecedented public health crisis, the biotech industry mobilized and collaborated like never before to create multiple safe and viable vaccine candidates in record time; not only that but the industry had a number of non-COVID-related clinical breakthroughs as well. As this Forbes article explains, it’s easy to see why biotech capital markets had their best year ever.
HoyleCohen’s Ty Summerlin works with a number of Biotech CEOs, and he is an excellent resource if you’d like to learn more about the intersection between biotech and capital markets.
This article was written by Forbes, an entity unrelated to HoyleCohen, LLC. The information herein is intended for educational purposes and has been selected by HoyleCohen due to the timeliness of the subject matter.